



(51) International Patent Classification:

C07D 487/10 (2006.01) A61P 35/00 (2006.01)
A61K 31/4035 (2006.01)

(21) International Application Number:

PCT/EP2022/075248

(22) International Filing Date:

12 September 2022 (12.09.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/243,267 13 September 2021 (13.09.2021) US

(71) Applicant: **ASTRAZENECA AB** [SE/SE]; SE-151 85
Södertälje (SE).(72) Inventors: **SMITH, James Michael**; AstraZeneca UK
Limited, 1 Francis Crick Avenue, Cambridge Biomedical
Campus, Cambridge CB2 0AA (GB). **ROBB, Graeme
Richard**; AstraZeneca UK Limited, 1 Francis Crick Av-
enue, Cambridge Biomedical Campus, Cambridge CB2
0AA (GB). **RAUBO, Piotr Antoni**; AstraZeneca UK Lim-
ited, 1 Francis Crick Avenue, Cambridge Biomedical Cam-

pus, Cambridge CB2 0AA (GB). **BARLAAM, Bernard
Christophe**; AstraZeneca UK Limited, 1 Francis Crick
Avenue, Cambridge Biomedical Campus, Cambridge CB2
0AA (GB). **CUMMING, Iain Alexander**; AstraZeneca
UK Limited, 1 Francis Crick Avenue, Cambridge Biomed-
ical Campus, Cambridge CB2 0AA (GB).

(74) Agent: **ASTRAZENECA INTELLECTUAL PROPER-
TY**; Milstein Building, Granta Park, Cambridge CB21 6GH
(GB).

(81) **Designated States** (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(54) Title: SPIROCYCLIC COMPOUNDS





Figure 1



(57) **Abstract:** The specification relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof. The specification also relates to processes and intermediates used for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.



(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*